Log in

Relevant bibliographies by topics / Bisphosphonate / Books

Books on the topic 'Bisphosphonate'

To see the other types of publications on this topic, follow the link: Bisphosphonate.

Author: Grafiati

Published: 4 June 2021

Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Bisphosphonate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Maria, Bijvoet Olav Leonardus, ed. Bisphosphonate on bones. Amsterdam: Elsevier, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Girard, Bruno. Exploring high dose effects of a bisphosphonate (HEBP) on osteogenesis in vitro. [Toronto: Faculty of Dentistry, University of Toronto], 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Catherine, Allison, and Canadian Coordinating Office for Health Technology Assessment., eds. An assessment of bisphosphonate drugs to manage pain secondary to bone metastases. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Marx, Robert E. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. Chicago: Quintessence Pub. Co., 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Rebecca, Wong, and Canadian Coordinating Office for Health Technology Assessment., eds. Bisphosphonate agents for the management of pain secondary to bone metastases: A systematic review of effectiveness and safety. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. 2nd ed. Chicago: Quintessence Pub. Co., Inc., 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ponte, Francesco Saverio De. Bisphosphonates and osteonecrosis of the jaw: A multidisciplinary approach. Milan: Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Chan, Cary Chung-Keung. Effects of cyclical parathyroid hormone (1-34) fragments and (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate treatment on bone in ovariectomized rats. Ottawa: National Library of Canada, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bartl, Reiner, Emmo von Tresckow, and Christoph Bartl. Bisphosphonat-Manual. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/3-540-31271-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Brunner, Kurt W., Herbert Fleisch, and Hans-Jörg Senn, eds. Bisphosphonates and Tumor Osteolysis. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83668-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Bartl, Reiner, Bertha Frisch, Emmo von Tresckow, and Christoph Bartl. Bisphosphonates in Medical Practice. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-69870-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Thürlimann, Beat. Bisphosphonates in Clinical Oncology. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59845-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Bilezikian, John P., and J. T. Grbic. Bisphosphonates and osteonecrosis of the jaw. Edited by New York Academy of Sciences. Boston, Mass: Published by Blackwell Pub. on behalf of the New York Academy of Sciences, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Bisphosphonates in clinical oncology: The development of pamidronate. Berlin: Springer, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

De Ponte, Francesco Saverio, ed. Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2083-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Fleisch, Herbert. Bisphosphonates in bone disease: From the laboratory to the patient. Bern: H. Fleish, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bisphosphonates in bone disease: From the laboratory to the patient. 3rd ed. New York: Parthenon Pub. Group, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Bisphosphonates in bone disease: From the laboratory to the patient. 2nd ed. New York: Parthenon Pub. Group, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bisphosphonates in bone disease: From the laboratory to the patient. 4th ed. San Diego: Academic Press, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Suzanne, Morphet, Canadian Coordinating Office for Health Technology Assessment., and Canadian Agency for Drugs and Technologies in Health., eds. Bisphosphonates and teriparatide for the prevention of osteoporotic fractures in postmenopausal women. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Björkroth, J. P. Evaluation of structure-activity relationships in drug design and an application to bisphosphonates. Helsinki: Suomalainen Tiedaekatemia, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Dirnagl, Lorenz. Unterschiede der Neoangiogenese bei Osteomyelitis, Osteoradionekrose und Bisphosphonat assoziierter Kiefernekrose in perinekrotischem Weichgewebe. [S.l: s.n.], 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Sparidans, Rolf W. Bisphosphonates: A chromatographic approach as a contribution to the clinical evaluation of pamidronate and olpadronate. [Tilburg]: Syntax Publishers, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

A, Wells George, and Canadian Agency for Drugs and Technologies in Health., eds. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: A meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Kruk, Dorothy. The costs and consequences of using bisphosphonates as prophylaxis against the sequelae of bone metastases secondary to breast cancer. Ottawa: National Library of Canada, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

Marx, Robert E. Oral & Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment. Quintessence Publishing (IL), 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ralston, Stuart H. Paget’s disease of bone. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0144.

Full text

Abstract:

Paget's disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones. This can lead to various complications including deformity, fracture, nerve compression syndromes, and osteoarthritis, although many patients are asymptomatic. Genetic factors play a key role in the pathogenesis of PDB. This seems to be mediated by a combination of rare genetic variants which cause familial forms of the disease and common variants which increase susceptibility to environmental triggers. Environmental factors which have been suggested to predispose to PDB include viral infections, calcium and vitamin D deficiency, and excessive mechanical loading of affected bones. The diagnosis can be made by the characteristic changes seen on radiographs, but isotope bone scans are helpful in defining disease extent. Serum alkaline phosphatase levels can be used as a measure of disease activity. Inhibitors of bone resorption are the mainstay of medical management for PDB and bisphosphonates are regarded as the treatment of choice. Bisphosphonates are highly effective at reducing bone turnover in PDB and have been found to heal osteolytic lesions, and normalize bone histology. Although bisphosphonates can improving bone pain caused by elevated bone turnover, most patients require additional therapy to deal with symptoms associated with disease complications. It is currently unclear whether bisphosphonate therapy is effective at preventing complications of PDB.

APA, Harvard, Vancouver, ISO, and other styles

28

Ralston, Stuart H. Paget’s disease of bone. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0144_update_001.

Full text

Abstract:

Paget’s disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones. This can lead to various complications including deformity, fracture, nerve compression syndromes, and osteoarthritis, although many patients are asymptomatic. Genetic factors play a key role in the pathogenesis of PDB. This seems to be mediated by a combination of rare genetic variants which cause familial forms of the disease and common variants which increase susceptibility to environmental triggers. Environmental factors which have been suggested to predispose to PDB include viral infections, calcium and vitamin D deficiency, and excessive mechanical loading of affected bones. The diagnosis can be made by the characteristic changes seen on radiographs, but isotope bone scans are helpful in defining disease extent. Serum alkaline phosphatase levels can be used as a measure of disease activity. Inhibitors of bone resorption are the mainstay of medical management for PDB and bisphosphonates are regarded as the treatment of choice. Bisphosphonates are highly effective at reducing bone turnover in PDB and have been found to heal osteolytic lesions, and normalize bone histology. Although bisphosphonates can improving bone pain caused by elevated bone turnover, most patients require additional therapy to deal with symptoms associated with disease complications. It is currently unclear whether bisphosphonate therapy is effective at preventing complications of PDB.

APA, Harvard, Vancouver, ISO, and other styles

29

Ponte, Francesco Saverio De. Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Ponte, Francesco Saverio De. Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Springer Milan, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

Rogers, Mike, Graham Russell, and Stuart Ralston. Bisphosphonates. Informa Healthcare, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

Russell, Bertrand. Bisphosphonates. Taylor & Francis Group, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

33

Thürlimann, Beat. Bisphosphonates in Clinical Oncology. Springer-Verlag, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

34

Senn, Hans-Jörg, Herbert Fleisch, and Kurt W. Brunner. Bisphosphonates and Tumor Osteolysis. Springer London, Limited, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

35

Reiner Bartl,Bertha Frisch,Emmo Tresckow. Bisphosphonates in Medical Practice. Springer, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

36

Bisphosphonates and Tumor Osteolysis. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bartl, Reiner, Christoph Bartl, and Emmo Tresckow. Bisphosphonat-Manual: Wirkungen - Indikationen - Strategien. Springer London, Limited, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

38

Bartl, Reiner, Emmo von Tresckow, and Christoph Bartl. Bisphosphonat-Manual: Wirkungen - Indikationen - Strategien. Springer, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

39

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text

Abstract:

Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presentation, staging and role of PET scanning, is described along with current treatment with chemotherapy and limited radiotherapy. Non-Hodgkin lymphoma is another heterogeneous group of diseases, divided into low-grade and high-grade pathology, and varying in their genetics, presentation, and management. Rituximab is a key component of chemotherapy regimens against B-cell lymphoma. Myeloma and other plasma cell dyscrasias are described, and treatment options reviewed. Myeloma remains incurable, but with appropriate management consistent with prolonged good quality life. Treatment includes chemotherapy, bisphosphonate therapy, analgesics and radiotherapy, Throughout this chapter is emphasised the importance of clinical trials in driving the rapid improvements in treatment of these diseases.

APA, Harvard, Vancouver, ISO, and other styles

40

BRUNNER, K. ED. Bisphosphonates & Tumor Osteolysis (Recent Results in Cancer Research). Springer, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

41

Thürlimann, Beat. Bisphosphonates in Clinical Oncology: The Development of Pamidronate. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

42

(Editor), Kurt W. Brunner, Herbert Fleisch (Editor), and Hans-Jörg Senn (Editor), eds. Bisphosphonates and Tumor-Osteolysis (Recent Results in Cancer Research). Springer, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

43

Bisphosphonates in Medical Practice: Actions - Side Effects - Indications - Strategies. Springer, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

44

Bartl, Reiner, Bertha Frisch, Christoph Bartl, and Emmo Tresckow. Bisphosphonates in Medical Practice: Actions - Side Effects - Indications - Strategies. Springer, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

45

Rubens, R., ed. Bisphosphonates And Metastatic Bone Disease (INTERNATIONAL CONGRESS, SYMPOSIUM/SEMINAR SERIES). Parthenon Publishing Group, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

46

Fleisch, Herbert. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. Elsevier Science & Technology Books, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

47

Otto, Sven. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

48

Bisphosphonates and osteonecrosis of the jaw: proceedings of an international conference. New York Academy of Science, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

49

Otto, Sven, and Sven Ed Otto. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents. Springer Berlin / Heidelberg, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

50

Otto, Sven. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates and Denosumab, and New Agents. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!